Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
Figure 3
Serial PET/CT images before and after brentuximab vedotin treatment. (a) Before treatment, showing mediastinal tumor progression, with metastases to left lung, left axillary, and supraclavicular lymph nodes. (b) Near-complete remission after 4 cycles of treatment, with a faint uptake over left lower neck. (c) Complete remission after 9 cycles of treatment.
